VJHemOnc Podcast

The importance of patient-reported outcomes in CAR-T recipients

CAR-T therapies have been approved for use in several hematological malignancies, and have greatly improved treatment options for patients, especially those with relapsed disease. While CAR-T products provide many benefits, it is also important to better understand the impact of these therapies on quality of life (QoL), including adverse events such as cytokine release syndrome (CRS) and neurotoxicity. 

In this exclusive podcast, Kedar Kirtane, MD, Laura Oswald, PhD, and Heather Jim, PhD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, discuss the importance of investigating patient-reported outcomes in CAR-T recipients. This discussion took place at the 4th International Workshop on CAR-T (iwCAR-T) meeting held in Tampa, FL.

CAR-T therapy in myeloma and lymphoma

CAR-T therapy has revolutionized the treatment landscape of several hematological malignancies, and ongoing clinical trials continue to provide valuable data on the safety and efficacy of these agents. At the 4th International Workshop on CAR-T (iwCAR-T) meeting held in Tampa, FL, several fascinating sessions took place, where leading experts discussed the application and challenges of CAR-T therapy in hematological malignancies, including lymphoma and multiple myeloma. 

In this exclusive podcast, Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, Suzanne Trudel, MD, MSc, Princess Margaret Cancer Centre, Toronto, Canada, Frederick Locke, MD, H. Lee Moffitt Cancer Center, Tampa, FL, and Krina Patel, MD, MSc, The University of Texas MD Anderson Cancer Center, Houston, TX, share key updates from the lymphoma and myeloma sessions held at this year’s meeting. The experts discuss several topics, including the benefit of CAR-T in second-line diffuse large B-cell lymphoma (DLBCL), strategies to overcome the challenges of CAR-T therapy in myeloma, patient selection for CAR-T therapy, and more.

CAR-T therapy in AML: challenges and future outlooks

Acute myeloid leukemia (AML) is an aggressive and heterogeneous hematological malignancy that poses many challenges for diagnosis and treatment. While the treatment landscape of AML has improved in recent years due to advances in therapy, there are still several hurdles to overcome to improve the efficacy of these novel agents.

In this podcast, you will hear from leading experts John DiPersio, MD, PhD, Washington University School of Medicine, Saint Louis, MO, Saar Gill, MD, PhD, University of Pennsylvania, Philadelphia, PA, and Rizwan Romee, MD, Dana-Farber Cancer Institute, Boston, MA, who share some insights on the challenges of CAR-T therapy in AML and strategies to overcome these. The experts also discuss CAR-NK therapy, NK-cell transduction, patient response to CAR-T therapy, and more. This discussion took place at the 4th International Workshop on CAR-T (iwCAR-T) meeting held in Tampa, FL.

The current state of CAR-T therapy in lymphoma

Over the last few decades, advances in immunotherapies including CAR-T therapy have revolutionized the treatment of patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL), and several clinical trials have demonstrated the efficacy of CAR-Ts in this field. Experts are also debating the possibility of bringing CAR-T therapy into earlier lines of treatment, and ongoing clinical trials are evaluating the benefits of this.

In this exclusive podcast, leading experts David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA, Caron Jacobson, MD, MMSc, Dana-Farber Cancer Institute, Boston, MA, and Loretta Nastoupil, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discuss the current state of CAR-T therapy in lymphoma. The experts comment on moving CAR-T therapy into earlier lines of treatment, and discuss clinical trial updates, including results from the TRANSFORM study (NCT03575351) and the ZUMA-12 study (NCT03761056). This discussion took place at the 4th International Workshop on CAR-T (iwCAR-T) meeting held in Tampa, FL.

Myeloma treatment updates from EHA 2022

While multiple myeloma remains a challenging disease to treat, there have been several advances in the field over the years. Novel immunotherapies, including CAR-T therapy, bispecific antibodies, and antibody-drug conjugates (ADCs), continue to transform the myeloma treatment landscape and provide patients with more hope. At the 2022 EHA Annual Meeting, there were several exciting updates presented, with a large focus being placed on clinical trials and novel immunotherapies.

In this exclusive podcast, Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, and Saad Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY, discuss key advances in myeloma treatment from this year’s EHA meeting, drawing focus on the DETERMINATION trial (NCT01208662) and the promise of novel immunotherapies.

Updates in classification and risk stratification in MDS

Classification and risk stratification are crucial for the management and treatment of patients with myelodysplastic syndromes (MDS). For many years, the gold standard for assessing disease risk has been the Revised International Prognostic Scoring System (IPSS-R). However, the recently-developed IPSS-Molecular (IPSS-M) has been evaluated and provides valuable information, improving overall risk assessment.

In this podcast, leading experts Rafael Bejar, MD, PhD, University of California San Diego, San Diego, CA, Aziz Nazha, MD, Amazon Web Services, Westlake, OH, Robert Hasserjian, MD, Massachusetts General Hospital, Boston, MA, and Jane Churpek, MD, MS, University of Wisconsin School of Medicine, Madison, WI, discuss updates in classification and risk stratification in MDS, including the value of the novel IPSS-M and the MDS Clinical Research Consortium Molecular Prognostic Tool. This discussion took place at the 1st International Workshop on Myelodysplastic Syndromes (iwMDS) held in Miami, FL.

Myeloma 2022: day one highlights

At the Myeloma 2022 meeting held in Scottsdale, AZ, there were several fascinating sessions that took place covering a variety of topics, including novel targets, T-cell engager therapy, myeloma at the single-cell level, the role of measurable residual disease (MRD), and more. Leading experts came together to discuss, debate, and answer questions, bringing you the latest in the field.

In this exclusive podcast, Keith Stewart, MB, ChB, Princess Margaret Cancer Centre, Toronto, Canada, Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone, New York, NY, and Faith Davies, MBBCh, MRCP, MD, FRCPath, NYU Langone, New York, NY, share some key highlights from day one at this year's meeting. The experts talk on updates in MRD and prognosis, antibody therapy for amyloidosis, and more. 

Immune dysregulation and targeting in MDS

Myelodysplastic syndromes (MDS) are a type of rare and heterogeneous hematological malignancy, and immune dysregulation plays a major role in the development of this disease and progression to acute myeloid leukemia (AML). Several novel targets are being explored in this field with the aim of increasing treatment options for patients and improving response to therapies. 

In this exclusive podcast, you will hear from leading experts Uwe Platzbecker, MD, Leipzig University Hospital, Leipzig, Germany, Alan List, MD, Precision BioSciences, Durham, NC, David Sallman, MD, Moffitt Cancer Center, Tampa, FL, and Daniel Starczynowski, PhD, Cincinnati Children’s Hospital, Cincinnati, OH, as they discuss immune dysregulation and targeting in MDS. This discussion took place at the 1st International Workshop on Myelodysplastic Syndromes (iwMDS) held in Miami, FL. 

The future of CAR-T therapy in ALL

Acute lymphoblastic leukemia (ALL) is an aggressive and heterogeneous disease with a high mortality rate. However, several advances have been made in recent years to improve treatment options for patients. Novel immunotherapies, such as chimeric antigen receptor T-cell (CAR-T) therapy and antibodies, are continuously being explored and have greatly changed the treatment landscape. 

 

In this exclusive podcast, you will hear from experts Noelle Frey, MD, MSCE, University of Pennsylvania, Philadelphia, PA, Bijal Shah, MD, Moffitt Cancer Center, Tampa, FL, and Shannon Maude, MD, PhD, Children's Hospital of Philadelphia, Philadelphia, PA, who discuss the future of CAR-T therapy in ALL, highlighting the impact of the approval of tisagenlecleucel (tisa-cel) in adult patients, the promise of allogeneic products, and more. This discussion took place at the 4th International Workshop on CAR-T (iwCAR-T) meeting held in Tampa, FL.

An insight into novel targets in myeloma and mechanisms of resistance to PIs and IMiDs

Multiple myeloma has seen many advances in recent years, and novel targeted agents are transforming the field. Several immunotherapies, including CAR-T therapy and T-cell engagers, are providing hope for patients, and novel targets are continuously being explored, especially in the relapsed/refractory setting.

In this exclusive podcast, leading experts Lawrence Boise, PhD, Winship Cancer Institute of Emory University, Atlanta, GA, and Paola Neri, MD, PhD, University of Calgary, Calgary, AB, Canada, discuss novel targets in multiple myeloma, including RAS and PIKfyve, and further comment on the epigenomics and epigenetics of resistance to proteasome inhibitors and IMiDs, as well as PROTAC therapy for difficult to manipulate targets.